Dr. Macrene Alexiades highlights that the FDA's approval of Evolysse Form and Evolysse Smooth marks Evolus's entry into the U.S. hyaluronic acid (HA) dermal filler market. These fillers, developed by Symatese, utilize a patented Cold-X technology, which involves cross-linking HA at low temperatures (between 0°C and 10°C) using 1,4-butanediol diglycidyl ether (BDDE). This method aims to preserve the natural HA structure, potentially reducing degradation and requiring less BDDE. Clinical trials have shown that these products are noninferior or even superior to the established filler Restylane-L.
Read full article here: https://www.healio.com/news/dermatology/20250214/fda-approves-two-hyaluronic-acid-fillers-for-nasolabial-folds